<DOC>
	<DOCNO>NCT02764515</DOCNO>
	<brief_summary>This multicenter , randomize , double blind , double-dummy control clinical trial aim compare clinical efficacy safety Kunxian Capsule , compound Chinese traditional medicine , active comparator , Methotrexate treatment rheumatoid arthritis . The primary end-point Kunxian Capsule inferior Methotrexate efficacy safety .</brief_summary>
	<brief_title>Kunxian Treatment Rheumatoid Arthritis</brief_title>
	<detailed_description>This prospective , multicenter , randomize , double blind , double-dummy control clinical trial.The goal compare clinical efficacy safety Kunxian Capsule , compound 4 ingredient Chinese herb-derived medication , active comparator , Methotrexate treatment mild moderate active rheumatoid arthritis.This study basically non-inferiority design , 428 subject enrol . All subject need fulfill inclusion criterion without exclusion criterion . Subjects randomize Kunxian Capsule treatment group Methotrexate treatment group.The dosage Kunxian Capsule use study 0.6g twice daily methotrexate dosage 10mg per week . All subject take medication 24 week . Diclofenic use salvage therapy case patient experience joint pain . The primary end-point proportion patient could achieve disease remission low disease activity treat Kunxian Capsule Methotrexate . All patient follow week 2,4,12 24 screening . Baseline information disease activity measure DAS28 score , CDAI score , SDAI score , ACR20 , ACR50 , ACR70 improvement , HAQ score , patient 's VAS score pain , lab test CRP , ESR , RF , CCP , blood urine routine test , liver well renal function test collect record . All measure perform follow-up visit except RF CCP . In addition , adverse event withdrawal happen visit record data analysis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Patients understand study protocol sign inform consent； 2 . Fulfill 1987 2010 ACR classification criterion RA； 3 . Male female patient , age range 4070 ; 4 . Male female plan child , permenopausal menopausal women； 5 . Patients mild moderate disease activity , ie , whose DAS28 range 3.25.1（ie , ESR＞28mm/h，or patient 15 swollen joint well 15 tender joints）； 6 . Without severe systemic disorder , severe pericardial effusion , pulmonary interstitial fibrosis , renal tubual acidosis , atrophic gastritis , autoimmune liver disease etc . 7 . Not included drug trial 1 month enrollment 1 . Pregnant woman woman prepare pregnant breast feeding； 2 . Patients active liver disease elevate liver enzymes eg , ALT and/or AST high 1.5 upper limit normal range ; 3 . Patients renal function abnormality , eg , serum creatinin high upper limit normal range； 4 . White blood cell count le 3.0×109/L，or anemia ( hemoglobin level lower 80g/L），or platelet count le 80×109/L，or hematological disease ; 5 . Patients chronic gastrointestinal diseases； 6 . Patients uncontrolled hypertension , metabolic disease diabetes ; 7 . History malignant tumor malignant tumor present ; 8 . With acute and/or chronic contagious diseases； 9 . Severe arrhythmia ECG test ; 10 . History adverse reaction Kunxian capsule , Tripterygium wilfordii Hook F. , methotrexate medication contain kunminshanhaitang ingredient； 11 . History psychiatric disease alcoholism drug abuse； 12 . Having diagnose systemic rheumatic disease ; 13 . Ever take immunosuppressive agent biological agent Tripterygium wilfordii Hook F medication contain kunminshanhaitang ingredient recent 3 months； 14 . Had ever take methotrexate Kunxian capsule 12 week could control arthritis remission； 15 . With condition consider inconsistent inclusion criterion accord investigator .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Kunxian Capsule</keyword>
	<keyword>efficacy</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>Methotrexate</keyword>
</DOC>